Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening

References

• Alonso, H., Bliznyuk, A. A., & Gready, J. E. (2006). Combining docking and molecular dynamic simulations in drug design. Medicinal Research Reviews, 26(5), 531–568.
   PubMed Web of Science ®Google Scholar
• Baell, J. B., & Holloway, G. A. (2010). New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of Medicinal Chemistry, 53(7), 2719–2740.
   PubMed Web of Science ®Google Scholar
• Certara, L. P. (1991–2012). SYBYL-X (Version 2.0). Ph iladelphia, PA: Rohm and Hass Company.
   Google Scholar
• Castelli, G., Pelosi, E., & Testa, U. (2017). Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy. OncoTargets and Therapy, 11, 131–155.
   PubMed Web of Science ®Google Scholar
• Chan, F. Y., Sun, N., Neves, M. A., Lam, P. C., Chung, W. H., Wong, L. K., … Wong, K. Y. (2013). Identification of a new class of FtsZ inhibitors by structure-based design and in vitro screening. Journal of Chemical Information and Modeling, 53(8), 2131–2140.
   PubMed Web of Science ®Google Scholar
• Charifson, P. S., Corkery, J. J., Murcko, M. A., & Walters, W. P. (1999). Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. Journal of Medicinal Chemistry, 42(25), 5100–5109.
   PubMed Web of Science ®Google Scholar
• Cheng, T., Li, X., Li, Y., Liu, Z., & Wang, R. (2009). Comparative assessment of scoring functions on a diverse test set. Journal of Chemical Information and Modeling, 49(4), 1079–1093.
   PubMed Web of Science ®Google Scholar
• Culhane, J. C., Wang, D., Yen, P. M., & Cole, P. A. (2010). Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. Journal of the American Chemical Society, 132(9), 3164–3176.
   PubMed Web of Science ®Google Scholar
• Duan, Y. C., Guan, Y. Y., Zhai, X. Y., Ding, L. N., Qin, W. P., Shen, D. D., … Liu, H. M. (2017). Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation. European Journal of Medicinal Chemistry, 126, 246–258.
   PubMed Web of Science ®Google Scholar
• Elhefnawi, M., ElGamacy, M., & Fares, M. (2012). Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors. BMC Bioinformatics, 13 (Suppl 17), S5.
   PubMed Web of Science ®Google Scholar
• Ferrari-Amorotti, G., Fragliasso, V., Esteki, R., Prudente, Z., Soliera, A. R., Cattelani, S., … Calabretta, B. (2013). Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. Cancer Research, 73(1), 235–245.
   Google Scholar
• Forneris, F., Binda, C., Adamo, A., Battaglioli, E., & Mattevi, A. (2007). Structural basis of LSD1-CoREST selectivity in histone H3 recognition. The Journal of Biological Chemistry, 282(28), 20070–20074.
   PubMed Web of Science ®Google Scholar
• Fu, X., Zhang, P., & Yu, B. (2017). Advances toward LSD1 inhibitors for cancer therapy. Future Medicinal Chemistry, 9(11), 1227–1242.
   PubMed Web of Science ®Google Scholar
• Hake, S. B., Xiao, A., & Allis, C. D. (2004). Linking the epigenetic 'language' of covalent histone modifications to cancer. British Journal of Cancer, 90(4), 761–769.
   PubMed Web of Science ®Google Scholar
• Han, C., Li, Z., Hou, J., Wang, Z., Xu, D., Xue, G., & Kong, L. (2018). Bioactivity evaluation of natural product α-mangostin as a novel xanthone-based lysine-specific demethylase 1 inhibitor to against tumor metastasis. Bioorganic Chemistry, 76, 415–419.
   PubMed Web of Science ®Google Scholar
• Hayami, S., Kelly, J. D., Cho, H. S., Yoshimatsu, M., Unoki, M., Tsunoda, T., … Hamamoto, R. (2011). Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. International Journal of Cancer, 128(3), 574–586.
   PubMed Web of Science ®Google Scholar
• Hazeldine, S., Pachaiyappan, B., Steinbergs, N., Nowotarski, S., Hanson, A. S., Casero, R. A., Jr., & Woster, P. M. (2012). Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1. Journal of Medicinal Chemistry, 55(17), 7378–7391.
   PubMed Web of Science ®Google Scholar
• Huang, J., & MacKerell, A. D. Jr. (2013). CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. Journal of Computational Chemistry, 34(25), 2135–2145.
   PubMed Web of Science ®Google Scholar
• Huang, J., Sengupta, R., Espejo, A. B., Lee, M. G., Dorsey, J. A., Richter, M., … Berger, S. L. (2007). p53 is regulated by the lysine demethylase LSD1. Nature, 449(7158), 105–108.
   PubMed Web of Science ®Google Scholar
• Huang, N., Shoichet, B. K., & Irwin, J. J. (2006). Benchmarking sets for molecular docking. Journal of Medicinal Chemistry, 49(23), 6789–6801.
   PubMed Web of Science ®Google Scholar
• Kontaki, H., & Talianidis, I. (2010). Lysine methylation regulates E2F1-induced cell death. Molecular Cell, 39(1), 152–160.
   PubMed Web of Science ®Google Scholar
• Kouzarides, T. (2007). Chromatin modifications and their function. Cell, 128(4), 693–705.
   PubMed Web of Science ®Google Scholar
• Kukol, A. (2011). Consensus virtual screening approaches to predict protein ligands. European Journal of Medicinal Chemistry, 46(9), 4661–4664.
   PubMed Web of Science ®Google Scholar
• Lee, J., Cheng, X., Swails, J. M., Yeom, M. S., Eastman, P. K., Lemkul, J. A., … Im, W. (2016). CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. Journal of Chemical Theory and Computation, 12, 405–413.
   PubMed Web of Science ®Google Scholar
• Lim, S., Janzer, A., Becker, A., Zimmer, A., Schule, R., Buettner, R., & Kirfel, J. (2010). Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis, 31(3), 512–520.
   PubMed Web of Science ®Google Scholar
• Lin, T., Ponn, A., Hu, X., Law, B. K., & Lu, J. (2010). Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene, 29(35), 4896–4904.
   PubMed Web of Science ®Google Scholar
• Lv, T., Yuan, D., Miao, X., Lv, Y., Zhan, P., Shen, X., & Song, Y. (2012). Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One, 7(4), e35065.
   PubMed Web of Science ®Google Scholar
• Lynch, J. T., Cockerill, M. J., Hitchin, J. R., Wiseman, D. H., & Somervaille, T. C. (2013). CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1. Analytical Biochemistry, 442(1), 104–106.
   PubMed Web of Science ®Google Scholar
• Milletti, F., Cheng, W. Y., Maes, T., Lunardi, S., DeMario, M., Pierceall, W. E., & Mack, F. (2016). Neuroendocrine gene transcript expression is associated with efficacy to lysine specific demethylase-1 inhibitor RG6016 in small cell lung cancer-derived cell lines. Cancer Research, 76(14), 4708–4708.
   Web of Science ®Google Scholar
• Mimasu, S., Sengoku, T., Fukuzawa, S., Umehara, T., & Yokoyama, S. (2008). Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Biochemical and Biophysical Research Communications, 366(1), 15–22.
   PubMed Web of Science ®Google Scholar
• MOE (2015). Molecular Operating Environment (Version 10). Montreal, Canada: Chemical Computing Group Inc.
   Google Scholar
• Mohammad, H. P., Smitheman, K. N., Kamat, C. D., Soong, D., Federowicz, K. E., Van Aller, G. S., … Kruger, R. G. (2015). A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell, 28(1), 57–69.
   PubMed Web of Science ®Google Scholar
• Mould, D. P., McGonagle, A. E., Wiseman, D. H., Williams, E. L., & Jordan, A. M. (2015). Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: Clinical significance and progress to date. Medicinal Research Reviews, 35(3), 586–618.
   PubMed Web of Science ®Google Scholar
• Mould, D. P., Alli, C., Bremberg, U., Cartic, S., Jordan, A. M., Geitmann, M., … Ogilvie, D. (2017). Development of (4-cyanophenyl)glycine derivatives as reversible inhibitors of lysine specific demethylase 1. Journal of Medicinal Chemistry, 60(19), 7984–7999.
   PubMed Web of Science ®Google Scholar
• Ooi, S. K., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., … Bestor, T. H. (2007). DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature, 448(7154), 714–717.
   PubMed Web of Science ®Google Scholar
• Pauli, I., dos Santos, R. N., Rostirolla, D. C., Martinelli, L. K., Ducati, R. G., Timmers, L. F., … Norberto de Souza, O. (2013). Discovery of new inhibitors of Mycobacterium tuberculosis InhA enzyme using virtual screening and a 3D-pharmacophore-based approach. Journal of Chemical Information and Modeling, 53(9), 2390–2401.
   PubMed Web of Science ®Google Scholar
• Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., … Schulten, K. (2005). Scalable molecular dynamics with NAMD. Journal of Computational Chemistry, 26(16), 1781–1802.
   PubMed Web of Science ®Google Scholar
• Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., … Shi, Y. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 119(7), 941–953.
   PubMed Web of Science ®Google Scholar
• Sorna, V., Theisen, E. R., Stephens, B., Warner, S. L., Bearss, D. J., Vankayalapati, H., & Sharma, S. (2013). High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. Journal of Medicinal Chemistry, 56, 9496–9508.
   PubMed Web of Science ®Google Scholar
• Speranzini, V., Rotili, D., Ciossani, G., Pilotto, S., Marrocco, B., Forgione, M., … Mattevi, A. (2016). Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features. Science Advances, 2, e1601017.
   PubMed Web of Science ®Google Scholar
• Varier, R. A., & Timmers, H. T. (2011). Histone lysine methylation and demethylation pathways in cancer. Biochimica et Biophysica Acta, 1815(1), 75–89.
   PubMed Web of Science ®Google Scholar
• Vianello, P., Sartori, L., Amigoni, F., Cappa, A., Faga, G., Fattori, R., … Mercurio, C. (2017). Thieno[3,2-b]pyrrole-5-carboxamides as new reversible inhibitors of histone lysine demethylase KDM1A/LSD1. Part 2: Structure-based drug design and structure–activity relationship. Journal of Medicinal Chemistry, 60(5), 1693–1715.
   PubMed Web of Science ®Google Scholar
• Wang, J., Hevi, S., Kurash, J. K., Lei, H., Gay, F., Bajko, J., … Chen, T. (2009). The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nature Genetics, 41(1), 125–129.
   PubMed Web of Science ®Google Scholar
• Wu, F., Zhou, C., Yao, Y., Wei, L., Feng, Z., Deng, L., & Song, Y. (2016). 3-(Piperidin-4-ylmethoxy)pyridine containing compounds are potent inhibitors of lysine specific demethylase 1. Journal of Medicinal Chemistry, 59(1), 253–263.
   PubMed Web of Science ®Google Scholar
• Zhao, Z. K., Yu, H. F., Wang, D. R., Dong, P., Chen, L., Wu, W. G., … Liu, Y. B. (2012). Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients. World Journal of Gastroenterology, 18(45), 6651–6656.
   PubMed Web of Science ®Google Scholar
• Zheng, Y. C., Duan, Y. C., Ma, J. L., Xu, R. M., Zi, X., Lv, W. L., … Liu, H. M. (2013). Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. Journal of Medicinal Chemistry, 56(21), 8543–8560.
   PubMed Web of Science ®Google Scholar
• Zheng, Y. C., Ma, J., Wang, Z., Li, J., Jiang, B., Zhou, W., … Liu, H. M. (2015). A systematic review of histone lysine-specific demethylase 1 and its inhibitors. Medicinal Research Reviews, 35(5), 1032–1071.
   PubMed Web of Science ®Google Scholar
• Zheng, Y. C., Yu, B., Chen, Z. S., Liu, Y., & Liu, H. M. (2016). TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy. Epigenomics, 8(5), 651–666.
   PubMed Web of Science ®Google Scholar
• Zhou, C., Kang, D., Xu, Y., Zhang, L., & Zha, X. (2015). Identification of novel selective lysine-specific demethylase 1 (LSD1) inhibitors using a pharmacophore-based virtual screening combined with docking. Chemical Biology & Drug Design, 85(6), 659–671.
   PubMed Web of Science ®Google Scholar
• Zhu, Q., Huang, Y., Marton, L. J., Woster, P. M., Davidson, N. E., & Casero, R. A. Jr. (2012). Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids, 42(2–3), 887–898.
   PubMed Web of Science ®Google Scholar